A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
Key facts
- Who runs it
- Pfizer
- Where
- Hollywood, New Haven, and New York, United StatesSee the 3 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 157 people enrolled
- Started
- 13 Dec 2023
- Ended
- 23 Sept 2025
- Type of study
- Interventional, 10 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- pdmFlu vaccine
- Placebo
- Licensed influenza vaccine
- Record updated
- 23 February 2026
Who can take part
- Age
- 18 years to 84 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study
Who cannot take part
- Does not meet seasonal influenza vaccine requirements per cohort
Where in United States
- Research Centers of AmericaHollywood, United States
- Pfizer Clinical Research Unit - New HavenNew Haven, United States
- NYU Langone HealthNew York, United States
About the trial
What the trial wants to find out
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine.
Read full original descriptionShow less
This study is seeking for participants who are:
* between the ages of 18 to 49 years old or 65 to 84 years old. * willing and able to follow with all scheduled visits, treatment plan, laboratory tests, lifestyle changes, and other study procedures. * healthy as confirmed by medical history, physical examinations, and the study doctor. * capable of signing informed consent.
Participants will receive either:
* the pdmFlu vaccine, * a licensed influenza vaccine * a placebo. A placebo does not have any medicine in it but looks just like the study medicine.
Participants will not know which vaccine they receive. Participants will receive the study vaccines as a single shot in the arm. The study will compare participant experiences to help understand if the pdmFlu vaccine is safe and effective. Participants will take part in this study for up to 13 months. During this time, the participants will receive the study vaccine and take part in follow-up visits.
The 10 groups in the trial
- pdmFlu vaccine 1Treatment being tested
Treatment: pdmFlu vaccine
- pdmFlu vaccine 2Treatment being tested
Treatment: pdmFlu vaccine
- pdmFlu vaccine 3Treatment being tested
Treatment: pdmFlu vaccine
- pdmFlu vaccine 4Treatment being tested
Treatment: pdmFlu vaccine
- pdmFlu vaccine 5Treatment being tested
Treatment: pdmFlu vaccine
- pdmFlu vaccine 6Treatment being tested
Treatment: pdmFlu vaccine
- pdmFlu vaccine 7Treatment being tested
Treatment: pdmFlu vaccine
- pdmFlu vaccine 8Treatment being tested
Treatment: pdmFlu vaccine
- PlaceboPlacebo, for comparison
- Licensed influenza vaccineExisting treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A PHASE 1, RANDOMIZED, OBSERVER-BLIND, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY ADULTS
- Record updated
- 23 February 2026